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New cis-fused chromeno pyrano[4,3-c]isoxazole derivatives have been synthesized by intramolecular
[1,3]-cycloaddition of the nitrones generated in situ from hydroxylamine derivatives and 7-O-prenyl
derivatives of 8-formyl-2,3-disubstituted chromenones using PEG-400 as a reaction medium under cat-
alyst-free conditions good to excellent yields. The structures were established by spectroscopic data and
further conﬁrmed by X-ray diffraction analysis. The results showed that compounds 4b, 4c,4d, 4e and 4k
exhibit very potent antiproliferative activity against MDA-MB-231 breast cancer cells. Compounds4a, 4c,
4e, 4i and 4k displayed potent inhibitory activity against human MCF-7 breast cancer cell lines. Com-
pounds 4h and 4i exhibited signiﬁcant anti-proliferative activity against human cervical cancer cell line,
HeLa. While 4b, 4d and 4j were active against human lung cancer cell line, A549. In addition, Compound
4j was found to be the most promising against A549 (Lung cancer) with IC50 value of 0.194 lM.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Cancer is one of the leading causes of death worldwide and
accounted for 7.6 million deaths (nearly 13% of all deaths) in
2008. Among all cancers, lung cancer has been recognized to be
one of the leading causes of death with 18.2% of all adulthood can-
cer deaths.1 Estrogen receptor (both ERa and ERb) related diseases,
breast cancer is the most commonly diagnosed malignant tumor in
women and accounting for approximately 24% of all female cancers
and the second most lethal cancer in women worldwide today.2
Cervical cancer, a slow growing squamous cell carcinoma caused
by human papillomavirus (HPV), is the second most common can-
cer that affects women after breast cancer.3 The mortality rate of
cervical cancer is high even though the percentage of cure is nearly
100%. For a long-term cancer, cytotoxic chemotherapeutic agents
are often used to inhibit cell growth and also possibly to induce
cancer cell apoptosis.4 Therefore, there is still an impetus to iden-
tify and develop more potent anti-cancer therapeutic agents with
improved properties such as enhanced and speciﬁc activity againstvarious cancers in the ﬁeld of medicinal chemistry. In recent years,
isoxazolidine heterocyclic synthesis have attracted tremendous
interest among researchers due to their potential applications in
medicinal chemistry (Fig. 1).5 A repertoire of small molecules con-
taining isoxazolidine moiety were reported that activate the tran-
scription levels comparable to those of the natural activation
domain in the regulatory network that controls gene-speciﬁc tran-
scription.6 These functionalized isoxazolidine derivatives are
known to posses various biological activities such as antitumor
activity (by DNA intercalation,7 N,O-nucleosides8), antimicrobial,9
anti-inﬂammatory,10 herbicidal,11 inhibition of HIV-1 replication.12
Chromeno-fused pyrano heterocyclic natural product compounds
display a wide range of biological applications.13 The present study
is in continuation to our earlier efforts14 on the synthesis of biolog-
ically important compounds using the 1,3-dipolar cycloaddition
reaction and the importance of isoxazolidines and chromanoisox-
azolidine derivatives. Although there are reports available for the
synthesis of substituted isoxazolidine, there seems to be no reports
on the synthesis of chromeno-fused pyranoisoxazolidine skeleton.
We have prepared new series of chromeno-annulated cis-fused
pyrano[4,3-c]isoxazole derivatives of high yields with excellent
stereoselectivity and investigated their primary biological activity
against four different (MDA-MB-231, MCF-7, HeLa, and A549) can-
cer cell lines.
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Figure 1. Isoxazolidine containing biologically active molecules.
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Scheme 2. Explanation of the observed stereochemistry.
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chromanoisoxazoles.15 Requisite 7-O-prenyl derivatives of 8-for-
myl-2,3-disubstituted chromenones14c,d (nitrone precursors) were
prepared from 2,3-disubstituted-7-hydroxychromeno aldehydes in
analogy to our previous work.
Initially the intramolecular [1,3]-cycloaddition of the nitrones 3
generated in situ by treatment of the 7-O-prenyl derivative of
8-formyl-2,3-disubstituted chromenones 1a with N-Benzyl
hydroxylamine 2a by using PEG-40016 as a reaction medium under
catalyst-free conditions afforded the corresponding cis-fused chro-
meno pyrano[4,3-c]isoxazole derivatives 4a in 85% yield with cis-
selectivity (Scheme 1).The reaction proceeds via a tandem intramolecular [1,3]-
cycloaddition reaction pathway. This reaction is highly stereo
selective affording exclusively chromeno cis-fused pyrano[4,3-
c]isoxazole derivatives (Scheme 1). These results can be explained
nicely by assuming that the reactions are governed by stereo elec-
tronic and steric effects.17 Thus more importantly the stereo spec-
iﬁcity of the formation of the major product 4a may be explained
by a stereo electronic effect via an endo-E-syn-transition structure
as shown in (Scheme 2). The main factors favoring an exo-Z-syn-
mode of addition are steric in nature due to the only in case of po-
lar substituents, which are also capable of entering into a second-
ary orbital interaction. The endo-E-syn mode of addition become
Figure 2. Characteristic NOE and energy-minimized structure of 4d.
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of 1,1-dimethyl oleﬁn, interplay of both these factors, that is,
methyl groups in exo-Z-syn- orientation caters for the steric inﬂu-
ences phenomenon of 1,3 allyl strain18 preferably accommodated
in the endo-E-syn- orientation leading to 4, complete stereo selec-
tivity is observed and a single adduct is obtained. In addition, the
stereochemistry of the product 4a was assigned on the basis of
1H NMR J-coupling constants and NOE studies. In the 1H NMR spec-
trum, the vicinal coupling constant JHa–Hb = 5.2 Hz in between Ha (d
4.47 ppm) and Hb (d 2.37 ppm) indicated an equatorial and axial
orientation of these protons, respectively, in a chair conformation,
which conﬁrmed that the six membered tetrahydropyran and ﬁve-
membered isoxazole rings are cis-fused. The six-membered ring
presumably adopts a twisted structure, consistent with the
observed vicinal coupling constants like JHb–Hc = 5.2 Hz, JHb–
Hd = 10.5 Hz, and the presence of x coupling of JHa–Hc = 1.5 Hz fur-
ther conﬁrmed the positions of Ha, Hb, Hc, and Hd as shown in Fig 2.
Further, the methyl group CH3(A) present at the ring junction in 4d
showed strong NOE cross peaks with Ha and Hb as well as weak
NOE cross peaks with CH3(B), which implies that Ha, Hb and methyl
group CH3(A) are with same conﬁguration. This clearly provides
the relative stereochemistry of all stereogenic centres (Fig. 2).
The energy-minimized structure of 4d is in full agreement with
the above NMR analysis 4d. Further, the spatial stereochemistry
of the product 4k was also conﬁrmed by single crystal X-ray dif-
fraction and the CCDC deposition number for 4k is 901862
(Fig. 3).19OO
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Figure 3. ORTEP diagram for the compound 4k, with displacement ellipsoids drawn
at 30% probability level.To investigate the synthesis of Chromeno pyrano[4,3-c]isoxaz-
oles by several nitrones (derived in situ from hydroxylamines
and 7-O-prenyl derivatives of 8-formyl-2,3-disubstituted chrome-
nones in PEG-400) were examined under various reaction condi-
tions and the results were summarized in Table 2. Initially, we
screened the reaction between N-Benzyl hydroxylamine 2a and
7-O-prenylated derivative of 8-formyl-2,3-dimethylchromen-
4-one 1a as starting materials using different catalysts to optimize
the reaction conditions (Table 1). It was found that 20 mol % of var-
ious Lewis acid/Bronsted acid catalysts and CH3CN were not much
useful to obtain the desired product in terms of reaction times,
yields due to rapid hydrolysis of prenyl ethers under strong acidic
conditions. Further optimization was performed to improve the
yield of the product. The best result was obtained when PEG-400
was used with high yield, low reaction time and optimum temper-
ature. However, in the absence of the catalyst the reaction pro-
ceeds with low yield even after longer reaction time (24 h). To
the best of our knowledge there are no reports on the synthesis
of pyranoisoxazole derivatives by using PEG-400 as a reaction
medium under catalyst-free conditions. The exclusive formation
of cis-isomer was established by the analysis of 1H NMR spectrum
and LC–MS analysis of the crude product 4a in all reaction condi-
tions (Table 1). Thus we have synthesized a novel series of chro-
meno cis-fused chromeno[4,3-c]isoxazoles (4a–l) in good to
excellent yields. All products are new and characterized by 1H,
13C NMR, IR and mass spectroscopy. In addition the stereochemis-
try of these compounds was established based on the X-ray diffrac-
tion analysis.
Inhibitory efﬁciency was tested for some of these chromeno cis-
fused pyrano[4,3-c]isoxazoles against four different cancer cell
lines like MDA-MB-231, MCF-7, A549 and HeLa. The MTT assay20
was performed following the previously reported protocol in a 96
well plate. Results of the in vitro anticancer activity were com-
pared with reference drug doxorubicin. Compounds 4f, 4h and 4i
exhibited good anti-proliferative activity against human cervical
cancer cell line, HeLa. Compounds 4b, 4c, 4d, 4e and 4f exhibited
promising anti-proliferative activity against human breast cancer
cell line, MDA-MB-231, while 4b, 4d and 4j were active towards
the human lung cancer cell line, A549. However, in case of com-
pound 4j the presence of N-substituent on the cyclohexyl group
showed very speciﬁc activity towards A549 cell line. In addition,
compounds 4a, 4c, 4e, 4i and 4k displayed promising inhibitory
activity against the human breast cancer cell line, MCF-7. These re-
sults indicated that the presence of N-substituent on the Bn and
PMB were found to exhibit promising activity and it also suggested
that aromatic monomethyl substituents and heterocyclic nitrones
showed good activity against HeLa (cervical) cancer cell line. It
was also observed that the presence of aromatic dimethyl substit-
uents and heterocyclic nitrones had good activity against MDA-
MB-231 cell line. Moreover, the presence of N-substituted p-alkyl
or methoxy benzyl group was found to have potent activity and
it also suggested that aromatic monomethyl, dimethyl substituents
and heterocyclic nitrones exhibited good activity against the breast
cancer cell line, MCF-7. In general, compounds with 2,3-dimethyl
and 3-methyl substitution on the chromenone moiety seem to be
a better ﬁt than a phenyl group at the 3-position. Cytotoxicity of
the compounds was determined on the basis of measurement of
in vitro growth inhibition of tumor cell lines in 96 well plates by
cell-mediated reduction of tetrazolium salt to water insoluble for-
mazan crystals using doxorubicin as a standard. The cytotoxicity
was assessed against a panel of four different human tumor cell
lines: A549 derived from human alveolar adenocarcinoma epithe-
lial cells (ATCC No. CCL-185), HeLa derived from human cervical
cancer cells (ATCC No. CCL-2), MDA-MB-231 derived from human
breast adenocarcinoma cells (ATCC No. HTB-26) and MCF7 derived
from human breast adenocarcinoma cells (ATCC No. HTB-22) using
Table 1
Effect of catalyst and solvent on intramolecular [1,3]-cycloaddition of the nitrones 7-O-prenylated derivative of 8-formyl-2,3-dimethylchromen-4-one 1a with N-Benzyl
hydroxylamine 2aa
O
O
O
CHO
CH3
CH3
N
OH
H
+
4a cis isomer only
O
O
O
CH3
CH3
N
O
H
HCatalyst, Solvent,
Temp
1a 2a
Entry Catalyst Solvent Temp (C)/time (h) Yieldb (%)
1 BF3.Et2O (20 mol %) CH3CN 70/4 33
2 CF3COOH (20 mol %) CH3CN 70/6.5 25
3 CAN (20 mol %) CH3CN 70/5 32
4 Iodine (20 mol %) CH3CN 70/4 30
5 NbCl5 (20 mol %) CH3CN 70/4.5 40
6 LiClO4 (20 mol %) CH3CN 70/6 68
7 PPh3.HClO4 (20 mol %) CH3CN 70/5 50
8 Sc(OTf)3 (20 mol %) CH3CN 70/6 35
9 Yb(OTf)3 (20 mol %) CH3CN 70/5 40
10 La(OTf)3 (20 mol %) CH3CN 70/5 38
11 None CH3CN 70/4 10
12 None PEG-400 70/4 85
a Reaction conditions: 1a (1 mmol), 2a (1 mmol), solvent (5 ml), Catalyst (20 mol %).
b Isolated yields.
Table 2
PEG-400 mediated synthesis of new Chromeno cis-fused pyrano[4,3-c]isoxazole a,b
Entry Aldehyde N-substituted hydroxylamines Productb Time (h) yieldc (%)
a
O
O
O
CHO
CH3
CH3
H
N
OH
O
O
O
N
O
CH3
CH3
H
H
4.0 85
b
O
O
O
CHO
CH3
CH3
N
H
OH
O
O
O
N
O
CH3
CH3
H
H
5.5 86
c
O
O
O
CHO
CH3
CH3 HN
OH
MeO
O
O
O
N
O
CH3
CH3
H
H
OMe
5.0 90
d
O
O
O
CHO
CH3
CH3 HN
OH
O
O
O
N
O
CH3
CH3
H
H
CH3
5.0 89
e
O
O
O
CHO
H
N
OH
O
O
O
N
OH
H
CH3
CH3
5.0 88
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Table 2 (continued)
Entry Aldehyde N-substituted hydroxylamines Productb Time (h) yieldc (%)
f
O
O
O
CHO
CH3
CH3 HN
OH
F
O
O
O
N
OH
H
F
CH3
CH3
6.5 82
g
O
O
O
CHO
CH3
CH3
H
N
OH
MeO
OMe
OMe
O
O
O
N
OH
H
OMe
OMe
OMe 5.0 72
h
O
O
O
CHO
CH3
H
N
OH
O
O
O
N
O
CH3
H
H
5.0 81
i
O
O
O
CHO
CH3
H
N
OH
O
O
O
O
N
O
CH3
H
H
OMe
5.0 84
j
O
O
O
CHO
CH3
H
N
OH
O
O
O
N
O
CH3
H
H
5.5 82
k
O
O
O
CHO
CH3
H
N
OH
O
O
O
N
O
CH3
H
H 5.0 83
l
O
O
O
CHO
CH3 HN
OH
MeO
OO
N
O
CH3
H
H
OMe
O
6.0 80
a Reagents and conditions: aldehyde 1 (1 mmol), hydroxylamines 2 (1.0 mmol), solvent (5 ml), 70–80 C.
b All product were characterized by 1H AND 13H NMR, IR, AND mass spectroscopy.
c Isolated yields.
N. K. Bejjanki et al. / Bioorg. Med. Chem. Lett. 23 (2013) 4061–4066 4065the MTT assay (Mosmann, 1983). The IC50 values (50% inhibitory
concentration) were calculated from the plotted absorbance data
for the dose-response curves. IC50 values (in lM) are expressed
as the average of two independent experiments (see Table 3).
In conclusion we have synthesized a series of novel chromeno
cis-fused pyrano[4,3-c]isoxazoles and evaluated their anti- prolif-
erative activity against human lung adenocarcinoma epithelial
A549, human breast adenocarcinoma MDA-MB-231, MCF-7, hu-
man Cervical cancer HeLa cell lines cell lines using an in vitro cyto-
toxicity assay. Among these, compounds 4c, 4e and 4k displayed
the most potent anti-proliferative activity against the humanbreast adenocarcinoma MDA-MB-231, MCF-7 cell lines, Com-
pounds 4h and 4i exhibited signiﬁcant anti-proliferative activity
against human Cervical cancer HeLa cell lines. In addition, Com-
pound 4j was found to be the most efﬁcacious against A549 (Lung
cancer) with IC50 value of 0.194 lM. Cell lines. Based on these pre-
liminary results, further synthesis of new chromeno cis-fused pyr-
ano[4,3-c]isoxazoles by changing the substituents on the
chromenone nucleus and isoxazole nucleus to enhance the anti-
cancer activity is currently being investigated and will be reported
in due course.
Table 3
Cytotoxicity evaluation of compounds 4a–4la
Compound
(lg mL1)
HeLa
(cervical)
MDA-MB231
(Breast)
MCF-7
(breast)
A549 (lung
cancer)
4a >100 14.45 5.78 17.93
4b >100 7.56 >100 8.96
4c >100 7.81 5.59 11.23
4d 18.19 5.64 26.54 8.92
4e >100 6.25 7.96 >100
4f‘ 9.54 7.9 10.1 12.79
4h 6.61 >100 >100 >100
4i 6.54 >100 7.38 29.4
4j 17.54 17.4 22.69 0.194
4k >100 >100 5.3 >100
4l >100 >100 >100 >100
Doxorubicin
standard
0.451 0.501 1.05 1.21
a Results are expressed as IC50 values in lM concentrations.
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